De novo development of gliomas in a child with neurofibromatosis type 1, fragile X and previously normal brain magnetic resonance imaging  by Zafar, Rabia et al.
ww.sciencedirect.com
R a d i o l o g y C a s e R e p o r t s 1 1 ( 2 0 1 6 ) 3 3e3 5Available online at wScienceDirect
journal homepage: ht tp: / /E lsevier .com/locate/radcrCase ReportDe novo development of gliomas in a child with
neurofibromatosis type 1, fragile X and previously
normal brain magnetic resonance imagingRabia Zafar MD, PhDa, Esther Y. Hsiao MDb, Kelly N. Botteron MDc,d,
Robert C. McKinstry MD, PhDe, David H. Gutmann MD, PhDb,*
a Department of Pediatrics, Washington University School of Medicine, Box 8116, 660 South Euclid Avenue, St. Louis, MO, USA
b Department of Neurology, Washington University School of Medicine, Box 8111, 660 S. Euclid Avenue, St. Louis, MO 63110, USA
c Department of Psychiatry, Washington University School of Medicine, Box 8134, 660 South Euclid Avenue, St. Louis, MO, USA
d Department of Radiology, Washington University School of Medicine, Box 8131, 66 South Euclid Avenue, St. Louis, MO, USA
e Mallinckrodt Institute of Radiology, Washington University School of Medicine, Box 8131, 66 South Euclid Avenue, St. Louis, MO, USAa r t i c l e i n f o
Article history:
Received 24 December 2015
Received in revised form
28 December 2015
Accepted 30 December 2015
Available online 2 February 2016
Keywords:
Inherited cancer syndrome
Astrocytoma
Neuroimaging
T2-hyperintensitiesCompeting Interests: R.C.M. is a consultant f
* Corresponding author.
E-mail address: gutmannd@neuro.wustl.
http://dx.doi.org/10.1016/j.radcr.2015.12.008
1930-0433/Copyright © 2016, the Authors. Pu
an open access article under the CC BY-NC-a b s t r a c t
Fifteen to 20% of children with neurofibromatosis type 1 develop low-grade glial neo-
plasms. However, since neuroimaging is not routinely obtained until a child is clinically
symptomatic, little is known about presymptomatic radiographic characteristics of gli-
omas in this at-risk population. Herein, we describe a child with neurofibromatosis type 1
who initially had normal brain imaging before the development of multifocal gliomas.
Comparison of these serial images demonstrated that brain tumors can arise de novo in
children with this cancer predisposition syndrome, further underscoring the limited
prognostic value of normal baseline magnetic resonance imaging.
Copyright © 2016, the Authors. Published by Elsevier Inc. under copyright license from the
University of Washington. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Children with the neurofibromatosis type 1 (NF1) inherited
tumor predisposition syndrome are prone to the development
of low-gradegliomas,whichoccur in15%-20%of thesechildren
[1]. Although tumors can arise anywhere within the central
nervous system, nearly 75% of these occur in the optic
pathway, 15% in the brainstem, and fewer than 5% elsewhere
in thebrain [2].Althoughhistologically similar to their sporadicor Siemens and Guerbet. T
edu (D.H. Gutmann).
blished by Elsevier Inc. u
ND license (http://creativcounterparts, the clinical course of NF1-associated gliomas is
generally more indolent [3]. Characteristically, these tumors
are hyperintense on T2-weighted sequences, isointense to
slightly hypointense on T1-weighted sequences and demon-
strate mass effect or expansion over time as well as variable
enhancement with gadolinium administration [2e4]. When
they arise in the brainstem, they are frequently asymptomatic
or cause only subtle symptoms (e.g., lethargy or localized
itching [5]), often discovered incidentally on magnetiche other authors have declared that no competing interests exist.
nder copyright license from the University of Washington. This is
ecommons.org/licenses/by-nc-nd/4.0/).
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produce cranial neuropathies, gait instability, or hydrocepha-
lus [4]. Most tumors do not require treatment, although some
may require shunting if hydrocephalus develops, or may
warrant surgical resection or chemotherapy in the setting of
clinical progression [6]. MRI screening in an asymptomatic
child is not routinely performed, as early detection does not
usually improve outcome, and radiographic findings have not
been shown to predict clinical behavior [7e9]. Since neuro-
imaging is not obtained, little is known about presymptomatic
radiographic characteristics of gliomas in children with NF1.Fig. 1 e Neuroimaging reveals thedenovodevelopment of a hypo
scansat 12 (T2-weighted), 26 (T2-weighted), and32 (fluid-attenua
thedevelopment ofmultifocal gliomasbeginning at 26months inCase report
A 20-month-old boy presented for initial evaluation of NF1. He
was born at ~38 weeks of gestation but was lethargic with sig-
nificant hypotonia and had poor feeding after birth, requiring
neonatal intensive careunit care. Thesefindings eventually led
to thediagnosisofFragileXsyndromeat9weeksofage.He then
developed profound developmental delay across all domains,
and only began to roll over at one year of age. He was noted to
havemultiple cafe-au-lait macules and right axillary freckling.
Both Fragile X and NF1 (c.2041C>T; p.Arg681*) were subse-
quently confirmed by molecular genetic testing.thalamic glioma. Coronal reconstructions of serial brainMRI
ted inversion recovery; FLAIR)monthsof age, demonstrating
regionspreviously appearingnormal at 12months (arrows).
Fig. 2 e Neuroimaging reveals radiographic progression of the hypothalamic glioma. Coronal reconstructions of serial
contrast-enhanced T1-weighted brain MRI scans, demonstrating progression of contrast enhancement in the left
hypothalamic glioma (arrows) at 26, 29, and 32 months of age.
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obtained at 12 months of age (Fig. 1). This was reviewed by his
clinical team as well as by neuroradiology (R.C.M.), and there
was no evidence of neoplasm. However, at 24 months, repeat
neuroimaging demonstrated a right optic nerve glioma (not
shown), a left hypothalamic glioma extending along the
lateral wall of the third ventricle, and a brainstem glioma
extending from the medulla to the upper cervical cord. Com-
parison of these 2 scans confirmed that there was no evidence
of these tumors on the initial scan.
Clinically-indicated MRI evaluations were subsequently
obtained at 26 and 29 months of age, with no evidence of
radiographic progression. However, at 32 months of age, a
repeat MRI revealed a significant increase in both the size and
enhancement of his hypothalamic lesion (Fig. 2). Based on this
radiographic progression, treatment was initiated with car-
boplatin and vincristine. Three months later, the brainstem
glioma increased in size, and his chemotherapy was changed
to Avastin and irinotecan, with no further radiographic or
clinical progression, now 18 months later.
Discussion
The serial images shown in Figure 1 demonstrate that brain
tumors can arise de novo in children with NF1. This observa-
tion, coupled with a prior report highlighting the limited prog-
nostic utility of a baselineMRI in asymptomatic individuals [8],
support the primary use of neuroimaging to investigate clini-
cally-symptomatic children with NF1 as revealed by serial
neurologic andophthalmologic examinations and to follow the
progression of previously identified brain tumors [9e11].r e f e r e n c e s
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